Ratings Moves: ING,...
Health Care: Drugs
Osiris Therapeutics Inc. (OSIR: NASDAQ)
$10.98 -0.09 | -0.81%
05/24/13 - 01:55 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -11.06M | 14.89M | 13.12M | -23.56M |
| Operating Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -2.36M | 1.20M | -790.00K | 55.15M |
| (Increase) Decrease in Inventories | -511.00K | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 2.19M | 991.00K | -298.00K | 220.00K |
| (Decrease) Increase In Payables | 246.00K | -912.00K | -3.40M | -1.95M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | -3.33M | -40.78M | -40.68M | -39.56M |
| Other Non-Cash Items | 1.11M | 3.43M | 1.68M | 2.46M |
| Net Cash From Continuing Operations | -13.27M | -20.44M | -32.78M | -5.47M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | -412.00K | -6.64M |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -13.27M | -20.44M | -33.19M | -12.11M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 17.00K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 13.50M | 20.80M | 33.60M | 54.18M |
| Purchases of Property, Plant & Equipment | -128.00K | -81.00K | -148.00K | -304.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | -51.19M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 9.74M |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 13.32M | 20.50M | 33.18M | 12.45M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 87.00K | 22.00K | 0.00 | 0.00 |
| Repayment of Long-Term Debt | -22.00K | 0.00 | -3.00K | -7.00K |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 75.00K | 129.00K | 148.00K | 39.00K |
| Net Cash From Financing Activities | 140.00K | 151.00K | 145.00K | 32.00K |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 193.00K | 219.00K | 136.00K | 366.00K |
Portfolios with OSIR
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- User2012
- ContributorStocks Rising On Unusual Vo...
- UserPharma
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Under-$10 Moving Hig...
- UserE*Trade
- Contributor200 day moving average stocks
Latest OSIR Headlines from TheStreet
- Osiris Therapeutics Inc. Stock Upgraded (OSIR) 03.28.13 | 05:03 am
- 4 Stocks Spiking on Unusual Volume 03.11.13 | 02:03 pm
- Biotech Stock Mailbag: Celldex, TG Therapeutics, Sarepta 03.08.13 | 06:03 am
- Osiris Therapeutics Inc. Stock Downgraded (OSIR) 03.08.13 | 04:03 am
- 10 Biotech Stocks With A History Of Beating Earning Expectations 01.10.13 | 07:01 pm
- 5 Under-$10 Stocks Due to Surge 12.27.12 | 01:12 pm
- The Next Big Thing In Biotech: Worst CEO Candidates
11.23.12 | 05:11 am - Biotech Stock Mailbag: More Amarin, MannKind, Orexigen 11.02.12 | 07:11 am
- Biotech Stock Mailbag: Sarepta Bear Story, Vertex, Osiris 10.05.12 | 06:10 am
- Biotech Stock Mailbag: Mela, Osiris, Talon 08.03.12 | 06:08 am
Press Releases for OSIR
- Osiris Therapeutics To Present At The Canaccord Genuity Musculoskeletal Conference - Business Wire 03.14.13 | 07:03 am
- Osiris Therapeutics Reports Fourth Quarter And Full Year 2012 Financial Results - Business Wire 03.06.13 | 08:03 am
- Osiris Therapeutics Establishes Direct Sales Force For Grafix® - Business Wire 03.01.13 | 07:03 am
- Osiris Therapeutics Announces Fourth Quarter And Full Year 2012 Financial Results Conference Call - Business Wire 02.22.13 | 05:02 pm
- Osiris Therapeutics Receives Title Of European Orphan Drug Designation For Prochymal® - Business Wire 02.19.13 | 07:02 am
- Osiris Therapeutics Successfully Defends Key Stem Cell Patent Challenge - Business Wire 02.18.13 | 07:02 pm
- Osiris Therapeutics To Present At The 24th Annual Piper Jaffray Healthcare Conference - Business Wire 11.20.12 | 04:11 pm
- Osiris Therapeutics Reports Third Quarter 2012 Financial Results - Business Wire 11.05.12 | 08:11 am
- Osiris Therapeutics Announces Third Quarter 2012 Financial Results Conference Call - Business Wire 10.29.12 | 04:10 pm
- Osiris Therapeutics Names Lode Debrabandere Chief Operating Officer - Business Wire 10.22.12 | 04:10 pm
Partner Headlines for OSIR
- Cell Therapy Leader Stephen Potter Talks Osiris, NeoStem And The Industry Itself - Seeking Alpha 03.19.13 | 09:03 am
- Acute Radiation Syndrome, Are We Prepared And Who Is Best Preparing Us? - Seeking Alpha 02.27.13 | 09:02 am
- Mid-Week Biopharma Catalyst Trades To Consider - Seeking Alpha 12.13.12 | 09:12 am
- Orphan Status Update from Pluristem - Analyst Blog - Zacks 11.27.12 | 07:11 pm
- Neutral on Osiris - Analyst Blog - NASDAQ 09.10.12 | 09:09 pm
- Cell Therapy Outlook Starting To Match Clinical Results - Seeking Alpha 08.21.12 | 09:08 am
- These Are Four of the Hottest Biotechs in the Market Right Now - Benzinga 07.05.12 | 01:07 pm
- Healthcare Biz Review: Osiris ACCUSED, Chelsea's BAD NEWS - Wall St. Cheat Sheet 07.04.12 | 08:07 am
- Osiris' Prochymal Encourages - Analyst Blog - Zacks 07.03.12 | 05:07 pm
- 6 Profitable Small Cap Healthcare Stocks Holding Large Cash Reserves - Seeking Alpha 06.22.12 | 07:06 pm
